Lung Cancer News

Preexisting antibodies in patients with non-small cell lung cancer treated with nivolumab or pembrolizumab appeared associated with both clinical benefit and the development of immune-related adverse events, according to a study published in JAMA Oncology.

The FDA expanded the approval of pemetrexed for injection to include its use in combination with pembrolizumab and platinum chemotherapy for first-line treatment of metastatic nonsquamous non-small cell lung cancer.

Adherence to annual lung cancer screening appeared low among U.S. veterans at high risk for the malignancy who had negative findings on baseline scan, according to results of a retrospective observational cohort study presented at CHEST Annual Meeting.

Patients with stage I to stage II small cell lung cancer achieved long-term survival with acceptable adverse effects following chemoradiotherapy and prophylactic cranial irradiation, according to a post-hoc secondary analysis of a multicenter, randomized phase 3 trial published in JAMA Oncology.

The Cuban-developed immunotherapy CIMAvax-EGF in combination with nivolumab appeared safe for patients with advanced non-small cell lung cancer, according to results from the first portion of a phase 1/phase 2 trial.

Patients with metastatic non-small cell lung cancer who received treatment at academic centers demonstrated significantly better 2-year survival rates than patients who were treated at community centers, according to results of a retrospective analysis.

Complications after invasive diagnostic procedures for lung abnormalities occurred twice as often in the real-world setting than in clinical trials that served as the basis for adoption of lung cancer screening with low-dose CT, according to results of a retrospective cohort study.

The number of adults screened via the wrong clinical pathway for lung cancer “greatly exceeded” those screened via U.S. Preventive Services Task Force recommendations for the same condition, according to findings recently published in the American Journal of Preventive Medicine.

The FDA granted accelerated approval to larotrectinib for the treatment of adults and children with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation.

A randomized phase 3 trial designed to compare durvalumab as monotherapy or in combination with tremelimumab with standard platinum-based chemotherapy for treatment-naive patients with metastatic non-small cell lung cancer failed to meet its primary endpoint of OS.